Page 8 - Gamida Cell News Today

Gamida Cell Ltd. , a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15,... | June 15, 2023

Gamida Cell (NASDAQ:GMDA – Get Rating) had its target price upped by HC Wainwright from $5.00 to $11.00 in a report issued on Wednesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Gamida Cell’s Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings […]

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Gamida Cell (NASDAQ:GMDA – Get Rating) had its target price lifted by HC Wainwright from $5.00 to $11.00 in a research note published on Wednesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Gamida Cell’s Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings […]

Gamida Cell (NASDAQ:GMDA – Get Rating) had its price target cut by Needham & Company LLC from $8.00 to $6.00 in a report issued on Thursday, The Fly reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the company. HC Wainwright lifted their price objective on […]

Gamida Cell Ltd. (NASDAQ:GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.

Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) – Equities researchers at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Gamida Cell in a research report issued to clients and investors on Wednesday, April 19th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings per share of $0.90 for the […]

Gamida Cell Ltd. , a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants... | April 18, 2023

Gamida Cell (NASDAQ:GMDA – Get Rating) had its price objective hoisted by stock analysts at HC Wainwright from $5.00 to $11.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Separately, Oppenheimer cut their price target on shares of Gamida Cell from $10.00 to $8.00 and set an “outperform” rating […]

Trio Petroleum Corp, an oil and gas exploration and development company focused on strategic, high growth energy projects in California, said that it priced its initial public offering of 2 million shares of its common stock at $3.